clinical trial · NCT07047690
A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
Galderma R&D·phase2·recruiting·n = 162
Systemic SclerosisNemolizumabPlacebo
brief summary
The main purpose of the study is to investigate the efficacy on cutaneous thickness and the safety of Nemolizumab in adult patients with systemic sclerosis after a 52-week treatment period and to select the optimal dose for this target population.
started
Feb 20, 2026
primary completion
May 28, 2028
completion
Jul 23, 2028
last updated
Mar 31, 2026
official title
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Nemolizumab in Adult Patients With Systemic Sclerosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol